Mathematical and computational models of drug transport in tumours

Journal of the Royal Society Interface

Volumn 11, Issue 94, 2014, Pages

  Groh, C M ^a,b   Hubbard, M E ^b   Jones, P F ^b   Loadman, P M ^c   Periasamy, N ^c   Sleeman, B D ^b,d   Smye, S W ^b,e   Twelves, C J ^f   Phillips, R M ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Computational modelling; Drug binding; Drug delivery; Drug transport; Mathematical modelling; Pharmacokinetic profiles

Indexed keywords

BINDING ENERGY; BLOOD VESSELS; CELLS; CYTOLOGY; DRUG DELIVERY; MATHEMATICAL MODELS; PHARMACOKINETICS; TOOLS;

CLINICAL TRIAL DESIGNS; COMPUTATIONAL MODEL; COMPUTATIONAL MODELLING; DRUG ADMINISTRATION; DRUG BINDING; DRUG TRANSPORT; FUNDAMENTAL MECHANISMS; PHARMACOKINETIC PROFILES;

TUMORS;

DOXORUBICIN; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD VESSEL; CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; NEOPLASM; PHARMACOKINETICS; PREDICTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; COMPUTATIONAL MODELLING; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; MATHEMATICAL MODELLING; METABOLISM; PHARMACOKINETIC PROFILES; TRANSPORT AT THE CELLULAR LEVEL;

COMPUTATIONAL MODELLING; DRUG BINDING; DRUG DELIVERY; DRUG TRANSPORT; MATHEMATICAL MODELLING; PHARMACOKINETIC PROFILES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84896933191     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.1173     Document Type: Article

References (36)

1. Vaupel P. 2008 Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl. 3), 21-26. (doi:10.1634/ theoncologist.13-S3-21)
2. Denekamp J, Dasu A, Waites A. 1998 Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv. Enzyme Regul. 38, 281-299. (doi:10.1016/S0065-2571(97)00015-0)
3. Minchinton AI, Tannock IF. 2006 Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583-592. (doi:10.1038/nrc1893)
4. Jain RK. 1999 Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241-263. (doi:10.1146/annurev.bioeng.1.1.241)
5. Pitt-Francis J et al. 2009 Chaste: a test-driven approach to software development for biological modelling. Comput. Phys. Commun. 180, 2452-2471. (doi:10.1016/j.cpc.2009.07.019)
6. Evans CJ, Phillips RM, Jones PF, Loadman PM, Sleeman BD, Twelves CJ, Smye SW. 2009 A mathematical model of doxorubicin penetration through multicellular layers. J. Theor. Biol. 257, 598-608. (doi:10.1016/j.jtbi.2008.11.031)
7. Evans ND, Errington RJ, Shelley M, Feeney GP, Chapman MJ, Godfrey KR, Smith PJ, Chappell MJ. 2004 A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math. Biosci. 189, 185-217. (doi:10.1016/j.mbs.2004.01.007)
8. El-Kareh AW, Secomb TW. 2000 A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2, 325-338. (doi:10.1038/sj.neo.7900096)
9. Lankelma J, Fernández Luque R, Dekker H, Schinkel W, Pinedo HM. 2000 A mathematical model of drug transport in human breast cancer. Microvasc. Res. 59, 149-161. (doi:10.1006/mvre.1999.2218)
10. Eikenberry S. 2009 A tumor cord model for doxorubicin delivery and dose optimization in solid tumors. Theor. Biol. Med. Model. 6, 16. (doi:10.1186/1742-4682-6-16)
11. Ribba B, Marron K, Agur Z, Alarcon T, Maini P. 2005 A mathematical model of doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results. Bull. Math. Biol. 67, 79-99. (doi:10.1016/j.bulm.2004.06.007)
12. Jackson TL. 2003 Intracellular accumulation and mechanism of action of doxorubicin in a spatiotemporal tumor model. J. Theor. Biol. 220, 201-213. (doi:10.1006/jtbi.2003.3156)
13. Chapman S, Shipley R. 2010 Multiscale modeling of fluid and drug transport in tumors. Bull. Math Biol. 72, 1464-1491. (doi:10.1007/s11538-010- 9504-9)
14. Swanson KR, Alvord Jr EC, Murray JD. 2002 Quantifying efficacy of chemotherapy of brain tumors with homogeneous and heterogeneous drug delivery. Acta Biotheor. 50, 223-237. (doi:10.1023/A:1022644031905)
15. Alarcon T, Byrne HM, Maini PK. 2005 A multiple scale model for tumor growth. Multiscale Model. Simul. 3, 440-475. (doi:10.1137/040603760)
16. Thurber GM, Weissleder R. 2011 A systems approach for tumor pharmacokinetics. PLoS ONE 6, e24696. (doi:10.1371/journal.pone.0024696)
17. Dordal MS, Ho AC, Jackson-Stone M, Fu YF, Goolsby CL, Winter JN. 1995 Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugs. Cytometry 20, 307-314. (doi:10.1002/cyto.990200406)
18. El-Kareh AW, Secomb TW. 2003 A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 5, 161-169. (Pubitemid 36369012)
19. El-Kareh AW, Secomb TW. 2005 Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia 7, 705-713. (doi:10.1593/neo.05118)
20. Nicholls GM, Clark BJ, Brown JE. 1992 Solid phase extraction and optimised separation of doxorubicin, epirubicin and their metabolites using reversedphase high performance liquid-chromatography. J. Pharm. Biomed. 10, 949-957. (doi:10.1016/0731-7085(91)80104-H)
21. Harada H, Xie XJ, Itasaka S, Zeng LH, Zhu YX, Morinibu A, Shinomiya K, Hiraoka M. 2008 Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumours. Biochem. Biophys. Res. Commun. 373, 533-538. (doi:10.1016/j.bbrc.2008.06.062)
22. Moore JV, Hasleton PS, Buckley CH. 1985 Tumor cords in 52 human bronchial and cervical squamous-cell carcinomas: inferences for their cellular kinetics and radiobiology. Br. J. Cancer 51, 407-413. (doi:10.1038/bjc.1985.55)
23. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. 2005 The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11, 8782-8788. (doi:10.1158/1078-0432.CCR-05- 1664)
24. Lee C, Kim JS, Waldman T. 2004 PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res. 64, 6906-6914. (doi:10.1158/0008-5472.CAN-04-1767)
25. Vestvik IK, Egeland TAM, Gaustad J-V, Mathiesen B, Rofstad EK. 2007 Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast-enhanced MRI. J. Magn. Reson. Imaging 26, 1033-1042. (doi:10.1002/jmri.21110)
26. Boyd JB. 2011 Chebyshev and Fourier spectral methods. New York, NY: Dover.
27. Trefethen LN. 2000 Spectral methods in Matlab. Philadelphia, PA: SIAM.
28. Speth PA, van Hoesel QG, Haanen C. 1988 Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15, 15-31. (doi:10.2165/00003088-198815010- 00002)
29. Robert J, Illiadis A, Hoerni B, Cano J-P, Durand M, Lagarde C. 1982 Pharmacokinetics of Adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur. J. Cancer Clin. Oncol. 18, 739-745. (doi:10.1016/0277-5379(82)90072-4)
30. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. 1983 Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and tretment protocols. Cancer Res. 43, 3417-3421. (Pubitemid 13061607)
31. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. 1993 Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin. Pharmacol. Ther. 53, 555-561. (doi:10.1038/clpt.1993.69)
32. Phillips RM, Bibby MC, Double JA. 1990 A critical appraisal of the predictive value of in vitro chemosensitivity assays. J. Natl. Cancer Inst. 82, 1457-1468. (doi:10.1093/jnci/82.18.1457)
33. 18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys. Med. Biol. 56, 2045-2057. (doi:10.1088/0031-9155/56/7/009)
34. Tannehill JC, Anderson DA, Pletcher RH. 1997 Computational fluid mechanics and heat transfer. Washington, DC: Taylor & Francis.
35. Rippley RK, Stokes CL. 1995 Effects of cellular pharmacology on drug distribution in tissues. Biophys. J. 69, 825-839. (doi:10.1016/S0006-3495(95) 79956-8)
36. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. 1989 Modeling analysis of the global and microscopic distribution of immunoglobin G, F(ab′)2, and Fab in tumors. Cancer Res. 49, 5656-5663. (Pubitemid 19256448)